These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24860837)

  • 1. Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia.
    Li C; Mu R; Lu XY; He J; Jia RL; Li ZG
    J Immunol Res; 2014; 2014():672126. PubMed ID: 24860837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.
    Yu HH; Wang LC; Lee JH; Lee CC; Yang YH; Chiang BL
    Rheumatology (Oxford); 2007 Sep; 46(9):1492-4. PubMed ID: 17673480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease.
    Villalta D; Bizzaro N; Bassi N; Zen M; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    PLoS One; 2013; 8(8):e71458. PubMed ID: 23951169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
    Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
    Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus.
    Schaper F; de Leeuw K; Horst G; Maas F; Bootsma H; Heeringa P; Limburg PC; Westra J
    Clin Exp Immunol; 2017 Jun; 188(3):412-419. PubMed ID: 28245520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
    Mok CC; Ho LY; Leung HW; Wong LG
    Transl Res; 2010 Dec; 156(6):320-5. PubMed ID: 21078493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus.
    Ahn SS; Jung SM; Yoo J; Lee SW; Song JJ; Park YB
    Rheumatol Int; 2019 Nov; 39(11):1937-1944. PubMed ID: 31552434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus.
    Su Y; Jia RL; Han L; Li ZG
    Clin Immunol; 2007 Jan; 122(1):115-20. PubMed ID: 17085075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
    Julkunen H; Ekblom-Kullberg S; Miettinen A
    Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.
    Draborg AH; Lydolph MC; Westergaard M; Olesen Larsen S; Nielsen CT; Duus K; Jacobsen S; Houen G
    PLoS One; 2015; 10(9):e0138753. PubMed ID: 26402865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between clinical and laboratory findings in patients with recent diagnosis of SLE according to the positivity of anti-dsDNA by the Crithidia luciliae method.
    Sarbu MI; Salman-Monte TC; Rubio Muñoz P; Lisbona MP; Almirall Bernabé M; Carbonell J
    Lupus; 2015 Oct; 24(11):1198-203. PubMed ID: 25716418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
    Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
    Pradhan VD; Patwardhan MM; Ghosh K
    Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India.
    Pradhan V; Pandit P; Rajadhyaksha A; Patwardhan M; Surve P; Kamble P; Lecerf M; Bayry J; Kaveri S; Ghosh K; Nadkar MY
    J Assoc Physicians India; 2016 May; 64(5):14-18. PubMed ID: 27735143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of cold-reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus.
    Winfield JB; Winchester RJ; Kunkel HG
    Arthritis Rheum; 1975; 18(6):587-94. PubMed ID: 1081876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study.
    Ren Y; Xie J; Lin F; Luo W; Zhang Z; Mao P; Zhong R; Liang Y; Yang Z
    Int Immunopharmacol; 2018 Jul; 60():189-193. PubMed ID: 29747124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients With Active Nephritis.
    Colliard S; Jourde-Chiche N; Clavarino G; Sarrot-Reynauld F; Gout E; Deroux A; Fougere M; Bardin N; Bouillet L; Cesbron JY; Thielens NM; Dumestre-Pérard C
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1263-1268. PubMed ID: 29045037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis.
    Bruschi M; Moroni G; Sinico RA; Franceschini F; Fredi M; Vaglio A; Cavagna L; Petretto A; Pratesi F; Migliorini P; Locatelli F; Pazzola G; Pesce G; Bagnasco M; Manfredi A; Ramirez GA; Esposito P; Murdaca G; Negrini S; Cipriani L; Trezzi B; Emmi G; Cavazzana I; Binda V; Fenaroli P; Pisani I; Garibotto G; Montecucco C; Santoro D; Scolari F; Mosca M; Tincani A; Candiano G; Prunotto M; Volpi S; Verrina E; Angeletti A; Ravelli A; Ghiggeri GM
    Rheumatology (Oxford); 2021 Jul; 60(7):3176-3188. PubMed ID: 33374003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.
    Saxena R; Sturfelt G; Nived O; Wieslander J
    Ann Rheum Dis; 1994 Oct; 53(10):659-65. PubMed ID: 7979578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.